Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05884320 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
A Phase 2 study of Gland and Salivary Gland Cancers, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05884320: Recruiting Phase 2 study of Gland and Salivary Gland Cancers, sponsored by M.D. Anderson Cancer Center.
NCT05884320 is a Phase 2 study of Gland and Salivary Gland Cancers that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05884320, a Phase 2 study of Gland and Salivary Gland Cancers, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
What NCT05884320 shows while recruiting
NCT05884320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Gland appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan is the first listed.
NCT05884320 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05884320 about?
NCT05884320 is a clinical study titled "Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers". To learn if sacituzumab govitecan can help to control salivary gland cancer.
What is the current status of trial NCT05884320?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-07-27. Estimated completion is 2028-07-31.
What conditions does trial NCT05884320 study?
This clinical trial studies the following conditions: Gland, Salivary Gland Cancers.
What interventions are being tested in trial NCT05884320?
The interventions under investigation include: Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT05884320?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05884320 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05884320's enrollment target sits among peer trials
30 1582nd of 2000 higher than 333 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI